Showing results (261-270 of 270) with videos related to
Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 270 results.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.Translational Lung Cancer Research|September 11, 2023
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary diseaseChengzhi Zhou, Yinyin Qin, Wei Zhao, et al.Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.Pageof 27